Investors

Shareholder Tools

 

Overview

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company’s lead product candidate is HEPLISAV, an investigational adult hepatitis B vaccine. For more information visit www.dynavax.com

Recent Press Releases

Apr 15, 2014
Dynavax Initiates Phase 3 Study of HEPLISAV-B(TM)

Mar 10, 2014
Dynavax Reports Fourth Quarter and Year End 2013 Financial Results

View all releases »

E-Delivery of Stockholder Communications

Beneficial stockholders

Registered stockholders

Corporate Presentation

Annual Report and Proxy
2013 Proxy Statement
2012 Form 10-K